Rosenson, Robert S.
Brewer, H. Bryan Jr
Barter, Philip J.
Björkegren, Johan L. M.
Chapman, M. John
Gaudet, Daniel
Kim, Daniel Seung
Niesor, Eric
Rye, Kerry-Anne
Sacks, Frank M.
Tardif, Jean-Claude
Hegele, Robert A.
Article History
First Online: 10 August 2017
Competing interests
: R.S.R. has received payment for consulting fees from Akcea, Amgen, CVS Caremark, Eli Lilly, Regeneron, and Sanofi; for speaker fees from Kowa; for grants or research support from Akcea, Amgen, Eli Lilly, Esperion, Regeneron, and The Medicines Company; and for royalties from UpToDate. H.B.B. Jr has received payment for consulting fees from AstraZeneca, Eli Lilly, InfraReDx, Merck, Pfizer, Roche, and Sanofi; for speaker fees or honoraria from AstraZeneca, Eli Lilly, InfraReDx, Merck, Roche, and Sanofi; and owns stock and/or has directorship roles in HDL Therapeutics and InfraReDx. P.J.B. has received payment for honoraria from Amgen, AstraZeneca, Merck, Pfizer, and Sanofi–Regeneron; for research grants from Merck and Pfizer; and is a member of the Advisory Boards of Amgen, Merck, and Pfizer. F.M.S. has received payment for consulting fees from AstraZeneca, MedImmune, Moderna, and Pfizer; for expert testimony from Aegerion and Pfizer; and is the inventor in a US patent on the use of apolipoprotein C-III, and is a Harvard University patent holder. J.-C.T. has received payment for consulting fees from DalCor, Pfizer, Sanofi, and Servier; for grants or research support from Amarin, AstraZeneca, DalCor, EliLilly, Esperion, Merck, Pfizer, Roche, Sanofi, and Servier; owns stock in DalCor; and has a patent on pharmacogenomic markers of response to dalcetrapib. The other authors declare no competing interests.